Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Shares Outstanding (Weighted Average) (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Shares Outstanding (Weighted Average) for 9 consecutive years, with $50.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) changed N/A to $50.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $50.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $50.8 million for FY2025, N/A changed from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $50.8 million at Soleno Therapeutics, up from $50.0 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $50.8 million in Q4 2025, with the low at $46.2 million in Q1 2025.